Author name: Leonardo Arias

BTIG analysts estimate that Elutia’s Elupro and Medtronic’s TYRX are competing for a $600 million opportunity in the U.S. cardiac rhythm management sector.

The prosecutor’s office opened an investigation in June, with charges including aggravated fraud and failure to report incidents that pose serious health risks.

The high court granted an expedited review of an appellate court finding that the president’s sweeping tariffs were illegal.

As Novo Nordisk cuts 9,000 people from its organization in a restructuring effort, BioSpace looks back on the Danish pharma company’s rise.

Hospital finances have been generally strong this year, but the future is precarious as expenses — including non-labor costs — rise, according to an analysis by Kaufman Hall.

These 27 markets, comprising countries across Asia, Europe and South America, together contributed some 12% of Lundbeck’s earnings in 2024.

Former CDC director Susan Monarez and former chief medical officer Debra Houry will appear in front of the Senate HELP Committee on Sept. 17.

Cullinan Therapeutics and Taiho Oncology’s zipalertinib elicited promising response rates in two mid-stage studies of non-small cell lung cancer patients with typical and uncommon EGFR mutations.

Jefferies analysts expect a regulatory filing for rocatinlimab later this year, with a product launch in 2026.

Novo Nordisk also lowered its full-year profit growth guidance in connection with the restructuring effort. The pharma now anticipates operating profit to grow from 4% to 10%, down from its prior projection of 10% to 16%.